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during 2008. Appeals were evaluated according to literature sent and justiﬁcations. 
The budgetary impact was measured. RESULTS: A total of 960 chemotherapy bills 
from this HP were evaluated totaling US$1,277,181.12. There was at least one point 
of recommended coverage denial in 471 (49%) either of materials, drugs or the entire 
procedure, representing US$157,965.77. Denial was based on the best available evi-
dence for each treatment. There were 100 appeals (US$47,889.11) following those 
denials, but 75% or US$35,939.53 was not reversed. We observed that contestations 
were more frequent for high cost drugs like Trastuzumab, Gemzar or Rituximab. The 
most frequent complaint was patient weight variation leading to the use of extra vials 
of these drugs, not previously approved. Interestingly, no such request was made for 
low-cost drugs. However, none of these variations resulted in dose increase larger than 
5%, not justifying the waste of nearly all the drug in the vial. In none of these appeals 
was any literature sent. The appeals reversed were basically bureaucratic cases in 
which the coverage was denied based of incorrect form ﬁllings or lack of any 
documentation. CONCLUSIONS: One in four denial appeals was reversed due to 
bureaucratic paper work. None of the other appeals was accompanied by sup- 
portive literature. Appeals are more frequent when high cost drugs are used in the 
chemotherapy.
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OBJECTIVES: To estimate annual expected economic burden (EEB) of treating 
advanced soft tissue sarcomas (STS) with trabectedin in Russia. METHODS: EEB 
of treating advanced STS with trabectedin was calculated in a model in comparison 
with EEB of bevacizumab for metastatic colorectal cancer (CRC) and sorafenib 
for advanced renal cancer (RC). All studied drugs are used for advanced cancer and 
have similar efﬁcacy of expected increase of survival for several months. The model 
was based on the following assumptions: 1) trabectedin is given to patients with a 
new case of STS revealed at advanced stage and resistant to ﬁrst-line therapy; 2) 
according to federal standards of care, bevacizumab is given to 80% of patients with 
a new case of metastatic CRC; and 3) sorafenib is given to all patients with a new 
case of metastatic RC. Number of new cases of advanced cancer was taken from the 
annual report about cancer morbidity and mortality in Russia. Dosing regimens of 
drugs were taken from clinical studies. Prices of bevacizumab and sorafenib were taken 
from RMBC database, price of trabectedin was proposed by the manufacturer. 
RESULTS: EEB of trabectedin was estimated to be 2.3 billion rubles (a. US$76.4 
million) per year, EEB of bevacizumab for metastatic CRC was 16.0–21.3 billion 
rubles (a. 533.1–US$710.8 million), EEB of sorafenib for metastatic RC was 5.8 
billion rubles (US$194.5 million) per year. CONCLUSIONS: EEB of trabectedin is 
less than of some other drugs for advanced cancer with comparable efﬁcacy that have 
already been recommended for use in a health care system. Bevacizumab is included 
into federal standards of care, sorafenib is included into Essential Drug List, that 
means that these drugs should be available to patients. Therefore trabectedin looks 
affordable for the system.
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OBJECTIVES: To calculate the NNT to avoid a recurrence of GIST after resection, 
to compare the cost of adjuvant treatment with imatinib (IM) with the cost of 
recurrence, and to estimate a budget impact from the Brazilian Public Health 
Care System (SUS) perspective. METHODS: Available relative risk reduction at 1 
year from the Z9001 clinical trial and historical rate of recurrence for no adjuvant 
treatment were applied to estimate absolute risk reduction and NNT. Adjuvant 
treatment effect was extrapolated to 3-year period as ongoing trials are investigating 
longer treatment duration (SSG XVIII). A 5-year time horizon was set for cost 
comparison and Budget Impact Analysis (BIA). Incremental Cost to Avoid 
Recurrence (ICAR) was deﬁned as the difference between the cost of adjuvant 
treatment (IM, monitoring) and the cost of recurrence (IM, surgery, monitoring, 
best supportive care). ICAR was applied to adjuvant GIST incidence for BIA. Epide-
miological data (incidence, proportion of resectables); health access, diagnosis 
and expected adjuvant treatment rates were obtained from literature. Resource utiliza-
tion and cost data came from ofﬁcial guideline and administrative databases, literature 
and expert opinion. Costs are reported in 2007 Euros. A 5% discount rate was 
applied. Univariate sensitivity analysis was performed. RESULTS: The NNT to 
avoid a recurrence was estimated at 2.1 based on extrapolated GIST recurrence 
risk proﬁle in Brazil. Cost of adjuvant treatment was a50,298 and the cost of a recur-
rence a61,998. Annual ICAR was a8,725. The annual impact on the Ministry of 
Health budget was 0.01%, which included impact on infrastructure (e.g. monitoring 
costs) of SUS. Results were sensitive to the recurrence rate and adjuvant treatment 
duration. CONCLUSIONS: Considering that imatinib is already reimbursed by 
SUS for metastatic/unresectable GIST, adjuvant therapy for primary GIST represents 
good value for money for the prevention of recurrence, and an annual budget impact 
of 0.01%.
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OBJECTIVES: The purpose of the study was to evaluate the cost effectiveness and 
budget impact of temsirolimus compared to interferon alpha-2A (IFN) in any given 
population of metastatic renal cell carcinoma (mRCC). METHODS: Economic evalu-
ations were performed from a US managed care perspective over a 30 months period. 
Cost of treatment was the summation of drug’s cost, administration cost, premedica-
tion cost, and cost of associated adverse events. Outcomes measure for economic 
evaluations was progression free life months gained. Cost effectiveness was conducted 
using a Markov state-transition model in TreeAge®. Time dependent transition prob-
abilities were calculated using multistate Kaplan Meier estimators based on clinical 
trial data. An Excel-based budget impact model was developed to compare two sce-
narios, one for the interferon scenario and one for the temsirolimus scenario. Inputs 
were obtained from SEER registry, clinical trial, and US census bureau. Sensitivity 
analyses were performed. RESULTS: The model yielded ICER $8944 per progression 
free life month gained. For a hypothetical managed care plan with 500,000 members, 
the Budget Impact model estimated 33 patients with mRCC. A 75% (n  25) of mRCC 
was eligible to receive ﬁrst line therapy. A 95% (n  24) eligible patients would be 
treated with IFN. Assuming that temsirolimus was available to 12% of eligible patients 
the expected 30 months cost would be US $18215.7 per patient compared 
with $15,557.90 had all patients been treated with IFN alone. CONCLUSIONS: 
Temsirolimus was found not to be dominantly cost effective compare to interferon 
alpha-2A. This ﬁnding is indicative of two challenges: 1) temsirolimus needs to be 
available at a reduced cost; 2) its threshold for cost-effectiveness needs to be adjusted 
according to relative clinical efﬁcacy. The budgetary impact of adding temsirolimus 
to health plan was estimated to be minimal. While its current availability allows new 
treatment options, temsirolimus may be too expensive to use in some managed care 
plans.
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OBJECTIVES: To perform a cost analysis comparing the management of adverse 
events (AEs) and their associated cost in current clinical practice of bevacizumab (BEV) 
 interferon alpha-2a (IFN) versus sunitinib (SUN) in patients with metastatic renal 
cell carcinoma (mRCC) in Spain. METHODS: A decision analytic model was devel-
oped to compare the costs derived from the management of 40 grade 3/4 AEs in 
patients with mRCC, using published data from published trials (BEV      IFN: Escudier 
B. Lancet 2007;370:2103–11. SUN: Motzer RJ. N Engl J Med 2007;356:115–24). 
The analysis was performed from the Spanish public hospitals perspective. Estimation 
of resources used in managing AEs was made through an Expert Panel. Cost evalua-
tion (a, 2009 values) included direct medical costs: outpatient visits, diagnostic and    
laboratory tests, hospitalization stays, surgeries, and medication. Unitary cost data 
were collected from Spanish Data Base of Sanitary Costs 2009 and Catalogue of            
Medicinal Products. RESULTS: Average cost of managing the grade 3/4 AEs per 
patient was a568 for BEVIFN and a940 for SUN. The per patient cost savings of 
a372 when using BEVIFN corresponds to a relative saving of 40% when compared 
to SUN. The main drivers for SUN costs were related to the management of laboratory 
abnormalities, anaemia, mucosal inﬂammation, decline in ejection fraction, diarrhea, 
thrombocytopenia, rash, epistaxis, and vomiting. In comparison, the main costs for 
BEVIFN were associated to the management of gastrointestinal perforation, bleeding, 
proteinuria, venous thromboembolic event, anorexia and anaemia. CONCLUSIONS: 
The costs of managing side effects of SUN treatment are signiﬁcantly greater than 
those for BEVIFN in Spain. When selecting treatment options, the management costs 
of these side effects may be an important factor to consider for health care payers.
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OBJECTIVES: New treatment options for advanced NSCLC can offer improved sur-
vival over standard chemotherapy and should also offer value for money. Bevaci-
zumab, a humanised monoclonal antibody (MAb) against VEGF, plus chemotherapy 
increases progression-free survival (PFS; median 6.8 months) in advanced NSCLC 
